Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use Setmelanotide. Talk to a licensed clinician before making health decisions.
What it is
Setmelanotide is an 8-amino-acid cyclic peptide analog of α-melanocyte-stimulating hormone (α-MSH) that selectively activates the melanocortin-4 receptor (MC4R). MC4R signaling in the hypothalamus is a key regulator of hunger and energy expenditure. In the approved genetic deficiencies, upstream signaling to MC4R is impaired, and setmelanotide bypasses the defect.
What the evidence shows
Two pivotal Phase 3 trials in POMC/PCSK1 and LEPR deficiencies (Lancet Diabetes Endocrinol 2020; 21 participants each, open-label with double-blind withdrawal) showed that 80% and 45% of participants, respectively, achieved at least 10% weight loss after approximately one year. Hunger scores also decreased markedly. Response is predicted by genetic confirmation of the target deficiencies.
Risks & unknowns
Common adverse events include injection-site reactions, nausea, vomiting, diarrhea, abdominal pain, and hyperpigmentation (darkening of skin and moles). Spontaneous penile erections in males and sexual adverse reactions have been reported. Because it bypasses normal MC4R regulation, it is restricted to the approved genetic indications.
Legal / regulatory status
Setmelanotide is FDA-approved as Imcivree for chronic weight management in patients 6 years and older with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. It is available only through specialty pharmacies and requires genetic diagnosis.